№ lp_1_2_31605
File format: docx
Character count: 15272
File size: 5272 KB
Year:
2025
Region / City:
West Glamorgan
Subject:
Integrated Discharge Strategy, Hospital Discharge, Patient Care
Document Type:
Report
Institution:
West Glamorgan Regional Partnership Board
Author:
Emily Warren, Helen St John
Target Audience:
Health and Social Care Professionals, Policy Makers
Period of Action:
May 2024 - March 2025
Approval Date:
28 January 2025
Date of Amendments:
Not specified
Context:
A report detailing the progress of the Integrated Discharge Strategy (IDS), which aims to improve discharge planning and reduce patient delays at hospitals.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2026
Region / City:
Global
Theme:
Energy efficiency, Compressed air systems
Document Type:
Product Information
Organization / Institution:
Kaeser Kompressoren
Author:
Kaeser Kompressoren
Target Audience:
Companies using compressed air systems
Period of Validity:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Programme:
Horizon Europe
Topic Title:
Improved reliability and optimised operations and maintenance for wind energy systems
Topic Identifier:
HORIZON-CL5-2026-02-D3-07
Type of Action:
Research and Innovation Action (RIA)
Call Opening Date:
16 September 2025
Call Deadline:
17 February 2026 (17:00 Brussels time)
Document Type:
Partner search form
Project Field:
Wind energy systems and smart grid integration
Technological Focus:
Digital twin modelling, artificial intelligence, smart grid simulation
Coordinator Organisation:
KYAMOS Ltd
Coordinator Country:
Cyprus
Consortium Partners:
KYAMOS Ltd; Frederick University; London School of Economics
Project Theme:
Reliability, optimisation, and predictive maintenance of wind turbines and wind farms
Target Partners:
Wind farm operators, O&M service providers, AI and wind turbine simulation researchers, smart grid specialists
Deadline for Expression of Interest:
31 January 2026
Contact Person:
Dr. Antonis Papadakis
Contact Email:
[email protected]
Live Attenuated Vaccines: Avoid Use In Those Who Are Clinically Immunosuppressed, Including Neonates
Year:
2016
Region / City:
Wales
Topic:
Vaccination, Immunosuppression
Document Type:
Medical/Health Advisory
Organization:
NHS Wales
Author:
Dr Chris Jones
Target Audience:
Healthcare professionals, General practitioners, Paediatricians, Oncologists, Rheumatologists, Immunologists, Nurses, Pharmacists, Medical Directors
Period of Validity:
Not specified
Approval Date:
4 May 2016
Modification Date:
Not specified
Contextual Description:
Medical advisory document warning healthcare professionals about the risks of live attenuated vaccines for immunosuppressed individuals, especially neonates and elderly patients.
Year:
2023
Region / City:
Temple University Hospital, USA
Subject:
EEG, Neuroscience, Medical Research
Document Type:
Research Article
Institution:
Temple University
Author:
Multiple contributors
Target Audience:
Researchers, Medical Professionals
Period of Data Collection:
14 years
Approval Date:
Not specified
Date of Latest Update:
Not specified
Year:
2023
Region / City:
Southern Health
Topic:
Medical guidelines for opioid patch use and syringe driver medication administration
Document type:
Clinical Protocol
Organization:
HHFT (Southern Health NHS Foundation Trust)
Author:
Southern Health NHS Foundation Trust
Target Audience:
Healthcare professionals involved in palliative care and medication administration
Period of validity:
April 2023
Date of approval:
April 2023
Date of changes:
April 2023
Year:
2026
Region / city:
United States
Topic:
Health assessment and risk management for potential infectious disease exposure
Document type:
Risk assessment form
Organization:
Centers for Disease Control and Prevention (CDC)
Author:
Centers for Disease Control and Prevention (CDC)
Target audience:
Healthcare providers, public health officials
Period of validity:
Ongoing
Approval date:
2026
Date of changes:
N/A
Description:
A health risk assessment form used by CDC to assess potential exposure to [SAMPLE VHF] and guide public health responses at points of entry.
Year:
2023
Region / city:
United Kingdom
Topic:
Healthcare, Infection Control
Document Type:
Standards
Organization:
National Health Service (NHS)
Author:
NHS Infection Prevention and Control (IP&C) Committee
Target Audience:
Healthcare Providers, Clinical Staff, Infection Control Teams
Period of validity:
Ongoing
Approval Date:
2023-01-01
Amendment Date:
2023-01-01
Year:
2023
Region / City:
Australia
Subject:
Healthcare, Medicare Benefits Schedule
Document Type:
Factsheet
Organization:
Department of Health and Aged Care
Author:
Department of Health and Aged Care
Target Audience:
Healthcare providers, referrers, private health insurance stakeholders
Effective Date:
1 November 2022
Amendment Date:
1 March 2023
Sample size:
10378 patients
Medical condition:
Prostate cancer
Subgroups:
Clinically significant prostate cancer (csPCa), Insignificant prostate cancer (Ins-PCa), All prostate cancer (PCa)
Variables analyzed:
Age, PSA level, Prostate volume (PV), PSA density (PSAD), PI-RADS score
Age categories:
<50; 50–60; 60–70; 70–80; ≥80 years
PSA categories:
<10; 10–20; 20–50; 50–100; ≥100 ng/mL; Unknown
Prostate volume categories:
<30; 30–40; 40–60; ≥60 ml; Unknown
PSA density categories:
<0.1; 0.1–0.15; 0.15–0.2; ≥0.2; Unknown
Imaging classification system:
PI-RADS (Prostate Imaging-Reporting and Data System)
Data type:
Quantitative clinical characteristics with counts and percentages
Medical field:
Urology / Oncology
Document type:
Statistical table of clinical study data
Year:
2026
Region:
International
Topic:
Exercise interventions and memory outcomes in depression
Document type:
Systematic review and meta-analysis
Authors:
Halappa, Lavretsky, Khatri, Imboden, Hoffman, Krogh, Oertel-Knochel, Bushert, Zheng, Sharma, Chen, Zhang
Target population:
Clinically diagnosed patients with depression
Study design:
Randomized controlled trials
Cognitive domains assessed:
Verbal memory, spatial memory
Intervention types:
Yoga, aerobic exercise, strength training, TMS
Duration of interventions:
4–16 weeks
Outcome measures:
RAVLT, DSTF, DSTB, WMS, BSRT, RCFT, VLMT
Methodological approach:
Leave-one-out meta-analysis, RoB 2.0 risk assessment, GRADE certainty rating
Year:
2021-2022
Region / city:
Abuja, Nigeria
Theme:
Traumatic brain injury, Clinical research
Document type:
Research article
Institution:
National Hospital Abuja
Author:
Not specified
Target audience:
Medical professionals, researchers
Period of validity:
N/A
Approval date:
N/A
Date of amendments:
N/A
Note:
Year
Subject:
Blood Borne Virus Testing, HIV, Hepatitis B, Hepatitis C
Document Type:
Procedure
Organization / Institution:
Canberra Health Services
Target Audience:
Medical Officers, nurses, midwives, students under supervision
Version:
1.5.0.0
Protocol Posting Date:
June 2024
CAP Laboratory Accreditation Program Protocol Required Use Date:
March 2025
Authors:
Gulisa Turashvili, MD, PhD; Uma G. Krishnamurti, MD, PhD; Barbara A. Crothers, DO; Giovanna A. Giannico, MD; Krisztina Hanley, MD; Anna Plotkin, MD; Anthony N. Karnezis, MD, PhD.
Note:
Accreditation Requirements
Date of Protocol Posting:
June 2024
Date of Required Use:
March 2025
Year:
2021
Region / City:
United Kingdom
Subject:
Assistance Dogs, Emergency Ambulance Services
Document Type:
Procedure
Organization / Institution:
South East Coast Ambulance Service NHS Foundation Trust
Author:
Not specified
Target Audience:
Ambulance Service Staff
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2026
Version:
NENC v2.0
Date published:
22 January 2026
Planned review date:
October 2027
Region:
North East and North Cumbria
Healthcare system:
NHS
Clinical area:
Neurology
Condition:
Amyotrophic lateral sclerosis
Medicine:
Riluzole
Document type:
Shared care protocol
Indication:
Extension of survival or time to mechanical ventilation in ALS
Target population:
Adults
Intended audience:
NHS healthcare professionals
Initiating authority:
Neurological specialist services
Regulatory reference:
NICE Technology Appraisal TA20
Prescribing setting:
Secondary to primary care transfer
Monitoring requirements:
Liver function tests, full blood count, urea and electrolytes
Route of administration:
Oral or enteral
Licensing status:
Licensed for ALS only
Year:
2024
Region / City:
Australia
Document Type:
Regulatory submission for PBS listing
Organization:
Biogen Australia Pty Ltd
Drug Name:
Omaveloxolone (Skyclarys®)
Indication:
Friedreich’s ataxia in adults and adolescents aged 16 years and older
Dosage Form:
Capsule 50 mg, oral administration
Regulatory Status:
Orphan drug status granted by TGA, EMA and FDA approvals
Submission Date:
26 June 2024
PBAC Meeting:
March 2025
Population:
Patients aged 16 years and older with Friedreich’s ataxia
Treatment Phase:
Initial and continuing treatment
Prescriber Type:
Dental, Medical Practitioners, Nurse Practitioners, Optometrists
Restriction Type:
Authority Required (telephone/online PBS Authorities system)
Clinical Criteria:
Genetic confirmation of FXN mutation, presence of clinical symptoms, management under a specialist or consultation with specialized unit if needed
Treatment Criteria:
Must be given with best supportive care, hemodynamically stable in case of cardiac history
Administrative Advice:
Queries directed to Services Australia, prescribing information available online
Year:
2023
Region / city:
Australia
Topic:
Chronic hyperkalaemia, kidney disease, sodium zirconium cyclosilicate
Document Type:
Submission to PBAC
Agency / organization:
AstraZeneca Pty Ltd
Author:
Not specified
Target audience:
Medical practitioners, healthcare professionals
Period of validity:
Ongoing, based on PBAC recommendation and PBS listing
Approval date:
1 September 2023
Date of amendments:
Not specified
Year:
2024
Region / city:
Humber and North Yorkshire ICB
Theme:
Hydroxychloroquine treatment protocol
Document type:
Clinical guideline
Organization / institution:
NHS
Author:
RDTC
Target audience:
NHS healthcare professionals
Effective period:
From the initiation date until March 2028
Approval date:
March 2025
Date of changes:
November 2023
Next review date:
March 2028
Year:
2018
Region / City:
British Columbia
Theme:
Medical Supplies Coverage for Gender Affirmation and Surgery
Document Type:
Guidelines
Organization:
Ministry of Social Development and Poverty Reduction
Author:
Unknown
Target Audience:
Medical practitioners (MDs, NPs)
Effective Date:
August 28, 2018
Approval Date:
August 28, 2018
Revision Date:
None
Acute Inpatient Psychiatric Admission Form for Patients Aged 10–17 with Neurodevelopmental Disorders
Patient Name:
____________________________________________
Date of Birth:
____________________
Home Address:
_________________________________________________________________________
Parent/Guardian Name/Phone/Email:
______________________________________________________
Expected Admission Type:
Voluntary / Involuntary
Referral for:
Acute Inpatient Psychiatric Treatment, approximately 30 days
Target Population:
Patients aged 10–17 with autism spectrum disorder, intellectual disability, or related neurodevelopmental disability
Current Psychiatric Provider:
UNC Psychiatry Outpatient (if applicable)
Diagnoses:
_____________________________________________________________________________
Current Medications:
____________________________________________________________________
Medical Problems:
______________________________________________________________________
Isolation Precautions:
No / Yes
Past Medical Hospitalizations or Surgeries:
__________________________________________________
Previous Psychiatric Treatment:
___________________________________________________________
Substance Use:
_________________________________________________________________________
Post-Treatment Residence Confirmed:
No / Yes
Department of Social Services / Child Protective Services Involvement:
_________________________
Consent for Medical Treatment:
___________________________________________________________
Last COVID Test:
___________________
Laboratory Results:
Within normal limits / Not done / Any abnormalities: ______________________
Pregnancy Status:
No / Yes
Seizure History:
No / Yes, well-controlled / Yes, uncontrolled
Last Vital Signs:
T______ P______ BP______ RR______ O2 Sat _____ Weight______ Height_______ BMI_________
Pending/Past Legal Problems:
_____________________________________________________________
ADL Support:
Independent / Needs Assistance with Eating, Hygiene, Walking (specify assist device)
Communication Method:
Verbally (sentences/words/phrases), Sign language, Pictures, Device, Gestures
Sensory Needs:
Hearing impaired / Visually impaired / Over/undersensitive to ____________________